

Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type (Type1, Type 2), By Treatment (Gene Therapy, Drug), By Drug (Spinraza, Zolgensma), By Route Of Administration, By Region, And Segment Forecasts, 2022 - 2030

https://marketpublishers.com/r/S30148EDCBEEN.html

Date: November 2022 Pages: 95 Price: US\$ 5,950.00 (Single User License) ID: S30148EDCBEEN

Abstracts

This report can be delivered to the clients within 2 Business Days

Spinal Muscular Atrophy Treatment Market Growth & Trends

The global spinal muscular atrophy treatment market size is expected to reach USD 18.0 billion by 2030, according to a new study by Grand View Research Inc. This is expected to expand at a CAGR of 18.6% from 2022 to 2030. This growth can be attributed to the increasing product approval and launches. For instance, in August 2020, the Food and Drug Administration approved Evrysdi (risdiplam) developed by Genentech, Inc., for the treatment of pediatric patients aged two months and older with spinal muscular atrophy (SMA).

In addition, in May 2020, Novartis AG received conditional approval to its SMA candidate Zolgensma (onasemnogene abeparvovec) from the European Commission (EC) to treat patients with SMA. It is only approved gene therapy in Europe. In March 2021, PTC Therapeutics, Inc., received marketing approval for Evrysdi (risdiplam) from the EMA for the treatment of patient with type1, 2, and 3 spinal muscular atrophy. Thus, increasing number of product approvals is expected to drive the spinal muscular atrophy treatment market.

Novartis AG is supporting SMA patients by offering medicine at free of cost through global Managed Access Program (MAP). This program provides 100 doses of



Zolgensma at free of charge to eligible SMA patients across continents including North America, South America, Asia, Australia, Europe, and Africa. Thus, presence of such supportive programs for Zolgensma strengthens promotional activities and also aid in generating revenue.

Global SMA newborn screening and easy access to diagnostic tools should be included in routine approach. This would ensure early diagnosis and timely access to treatment. For instance, in July 2021, a charlotte baby received a breakthrough gene therapy treatment for Spinal Muscular Atrophy (SMA) at UNC Medical Center in Chapel Hill, N.C., after diagnosis with spinal muscular atrophy through Early Check newborn screening program. Such screening programs are expected to boost early diagnosis and treatment of disease.

Moreover, there are several extensive research collaborations undertaken by pharmaceutical companies with research institutes for developing novel therapies for the treatment of spinal muscular atrophy patients. For instance, in March 2021, PTC Therapeutics, Inc., and The Spinal Muscular Atrophy Foundation entered into research collaboration to advance scientific research and developing new treatment to treat patients with SMA.

However, high costs associated with the treatment and low availability of participant for clinical trial purposes may restrain market growth over the forecast period. The high cost related to research and development of an orphan drug is a major factor of rising prices of product. For instance, the most commonly used drug Spinraza costs around USD 125,000 per injection and USD 750,000 annually. Furthermore, Zolgensma (AVXS-101) costs USD 2.1 million for one time treatment.

Spinal Muscular Atrophy Treatment Market Report Highlights

By type, the type-1 segment held the largest market share in 2021 due to higher prevalence and wide availability of products for the treatment of patients with type-1 spinal muscular atrophy

By treatment, the gene therapy segment is expected to be the fastest growing segment over the forecast period due to increase market penetration. Zolgensma is the only approved gene therapy in 37 countries to treat patient with SMA

By drug, the Spinraza segment dominated the market in 2021 due to presence



of supportive reimbursement policies and increasing awareness about products. Currently, Spinraza is applicable for full reimbursement in three European countries Italy, Norway, Netherlands

By route of administration, the injection segment dominated the market in 2021 due to high safety, efficacy, and tolerability associated with infusion drugs to SMA patients through this route of administration

Asia Pacific is expected to be the fastest growing region during the forecast period. The growth of region is attributable to the entry of new products into the region. For instance, in July 2021, F. Hoffmann-La Roche Ltd launched Evrysdi (risdiplam) for the treatment of patient with spinal muscular atrophy in India



Contents

CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market segmentation
- 1.1.1 Estimates and forecast timeline
- 1.2 Research Methodology
- **1.3 Information Procurement**
- 1.3.1 Purchased database
- 1.3.2 GVR'S internal database
- 1.3.3 Secondary sources
- 1.3.4 Primary research
- 1.3.5 Details of primary research
- 1.3.6 List of primary sources
- 1.4 Information or data analysis
- 1.4.1 Data analysis models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
 - 1.6.1 Commodity flow analysis
 - 1.6.1.1 Approach 1: Commodity Flow Approach
 - 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
- 1.7 Global Market: CAGR Calculation
- 1.8 Research Assumptions
- 1.9 List of Secondary Sources
- 1.10 List of Abbreviations
- 1.11 Objectives
 - 1.11.1 Objective
 - 1.11.2 Objective
 - 1.11.3 Objective
 - 1.11.4 Objective

CHAPTER 2 EXECUTIVE SUMMARY

2.1 Market Summary

CHAPTER 3 MARKET VARIABLES, TRENDS & SCOPE

- 3.1 Market Lineage Outlook
 - 3.1.1 Parent market outlook



- 3.2 Regulatory framework
- 3.3 Penetration and Growth Prospect Mapping
- 3.4 Pipeline Analysis
- 3.5 Market Dynamics
- 3.5.1 Market driver analysis
- 3.5.2 Market restraint analysis
- 3.6 PESTEL Analysis

CHAPTER 4 GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET -SEGMENT ANALYSIS, BY TYPE, 2018 - 2030 (USD MILLION)

4.1 Global Spinal Muscular Atrophy Treatment Market: Type Movement Analysis

4.2 Type

4.2.1 Type 1 market estimates and forecast, 2018 - 2030 (USD Million) 4.3 Type

4.3.1 Type 2 market estimates and forecast, 2018 - 2030 (USD Million) 4.4 Type

4.4.1 Type 3 market estimates and forecast, 2018 - 2030 (USD Million) 4.5 Type

4.5.1 Type 4 market estimates and forecast, 2018 - 2030 (USD Million)

CHAPTER 5 GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET -SEGMENT ANALYSIS, BY TREATMENT, 2018 - 2030 (USD MILLION)

5.1 Global Spinal Muscular Atrophy Treatment Market: Treatment Movement Analysis5.2 Gene Therapy

5.2.1 Gene therapy market estimates and forecast, 2018 - 2030 (USD Million) 5.3 Drug

5.3.1 Drug market estimates and forecast, 2018 - 2030 (USD Million)

CHAPTER 6 GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET -SEGMENT ANALYSIS, BY DRUG, 2018 - 2030 (USD MILLION)

6.1 Global Spinal Muscular Atrophy Treatment Market: Drug Movement Analysis6.2 Spinraza

6.2.1 Spinraza market estimates and forecast, 2018 - 2030 (USD Million)6.3 Zolgensma (AVXS-101)

6.3.1 Zolgensma (AVXS-101) market estimates and forecast, 2018 - 2030 (USD Million)



6.4 Evrysdi

6.4.1 Evrysdi market estimates and forecast, 2018 - 2030 (USD Million) 6.5 Others

6.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

CHAPTER 7 GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET -SEGMENT ANALYSIS, BY ROUTE OF ADMINISTRATION, 2018 - 2030 (USD MILLION)

7.1 Global Spinal Muscular Atrophy Treatment Market: Route of Administration Movement Analysis

7.2 Oral

7.2.1 Oral market estimates and forecast, 2018 - 2030 (USD Million)

7.3 Injection

7.3.1 Injection market estimates and forecast, 2018 - 2030 (USD Million)

CHAPTER 8 SPINAL MUSCULAR ATROPHY TREATMENT MARKET: SEGMENT ANALYSIS, BY REGION, 2018 - 2030 (USD MILLION)

8.1 Spinal Muscular Atrophy Treatment Market: Regional Movement Analysis 8.1.1 North America

0.1.1 North America

8.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)8.1.1.2 U.S.

8.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million) 8.1.1.3 Canada

8.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million) 8.1.2 Europe

8.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million) 8.1.2.2 U.K.

8.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)

8.1.2.3 Germany

8.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million) 8.1.2.4 France

8.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million) 8.1.2.5 Spain

8.1.2.5.1 Spain market estimates and forecast, 2018 - 2030 (USD Million) 8.1.2.6 Italy

8.1.2.6.1 Italy market estimates and forecast, 2018 - 2030 (USD Million) 8.1.3 Asia Pacific



8.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)

8.1.3.2 Japan

8.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million) 8.1.3.3 China

8.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)

8.1.3.4 India

8.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)

8.1.3.5 Australia

8.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million) 8.1.3.5 South Korea

8.1.3.5.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million) 8.1.4 Latin America

8.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million) 8.1.4.2 Brazil

8.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)

8.1.4.3 Mexico

8.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million) 8.1.4.4 Argentina

8.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million) 8.1.5 Middle East & Africa

8.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)

8.1.5.2 South Africa

8.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million) 8.1.5.3 Saudi Arabia

8.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million) 8.1.5.5 United Arab Emirates

8.1.5.5.1 United Arab Emirates market estimates and forecast, 2018 - 2030 (USD Million)

CHAPTER 9 GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET: COMPETITIVE ANALYSIS

9.1 Recent Developments and Impact Analysis, by Key Market Participants

- 9.1.1 Major deals & strategic alliances analysis
 - 9.1.1.1 New Product Launches
 - 9.1.1.2 Mergers and Acquisitions
 - 9.1.1.3 Partnerships & Agreements
- 9.2 Company Categorization



- 9.2.1 Innovators
- 9.2.2 Market Leaders
- 9.2.3 Emerging Players
- 9.2.4 Heat Map Analysis
- 9.3 Company Market Position Analysis
- 9.4 Vendor Landscape
 - 9.4.1 List of Key Distributors and Channel Partners
- 9.4.2 List of Potential End Users
- 9.4.3 Key Company Market Share Analysis, 2021
- 9.5 Company Market Share, 2021
 - 9.5.1 Competitive Dashboard Analysis
- 9.6 Private Companies
- 9.6.1 List of Key Emerging Companies
- 9.6.2 Regional Network Map
- 9.7 Company Profiles
 - 9.7.1 Biogen
 - 9.7.1.1 Company overview
 - 9.7.1.2 Financial performance
 - 9.7.1.3 Product benchmarking
 - 9.7.1.4 Strategic initiatives
 - 9.7.2 Novartis AG
 - 9.7.2.1 Company overview
 - 9.7.2.2 Financial performance
 - 9.7.2.3 Product benchmarking
 - 9.7.2.4 Strategic initiatives
 - 9.7.3 Ionis Pharmaceuticals Inc.
 - 9.7.3.1 Company overview
 - 9.7.3.2 Financial performance
 - 9.7.3.3 Product benchmarking
 - 9.7.3.4 Strategic initiatives
 - 9.7.4 Biohaven Pharmaceuticals
 - 9.7.4.1 Company overview
 - 9.7.4.2 Financial performance
 - 9.7.4.3 Product benchmarking
 - 9.7.4.4 Strategic initiatives
 - 9.7.5 F. Hoffmann-La Roche Ltd
 - 9.7.5.1 Company overview
 - 9.7.5.2 Financial performance
 - 9.7.5.3 Product benchmarking



- 9.7.5.4 Strategic initiatives
- 9.7.6 Cytokinetics
- 9.7.6.1 Company overview
- 9.7.6.2 Product benchmarking
- 9.7.6.3 Strategic initiatives
- 9.7.7 Scholar Rock, Inc.
 - 9.7.7.1 Company overview
- 9.7.7.2 Financial performance
- 9.7.7.3 Product benchmarking
- 9.7.8 PTC Therapeutics
- 9.7.8.1 Company overview
- 9.7.8.2 Financial performance
- 9.7.8.3 Product benchmarking
- 9.7.8.4 Strategic initiatives
- 9.7.9 NMD Pharma A/S
 - 9.7.9.1 Company overview
 - 9.7.9.2 Financial performance
 - 9.7.9.3 Product benchmarking
 - 9.7.9.4 Strategic initiatives





List Of Tables

LIST OF TABLES

Table 1 List of Secondary Sources

Table 2 List of Abbreviation

Table 3 Global Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 4 Global Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 5 Global Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 6 Global Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 7 North America Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 8 North America Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 9 North America Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 10 North America Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 11 U.S. Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 12 U.S. Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 13 U.S. Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 14 U.S. Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 15 Canada Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 16 Canada Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 17 Canada Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 18 Canada Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 19 Europe Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030



(USD Million)

Table 20 Europe Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 21 Europe Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 22 Europe Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 23 Germany Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 24 Germany Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 25 Germany Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 26 Germany Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 27 U.K. Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 28 U.K. Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 29 U.K. Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 30 U.K. Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 31 France Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 32 France Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 33 France Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 34 France Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 35 Italy Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 36 Italy Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 37 Italy Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 38 Italy Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)



Table 39 Spain Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 40 Spain Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 41 Spain Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 42 Spain Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 43 Asia Pacific Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 44 Asia Pacific Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 45 Asia Pacific Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 46 Asia Pacific Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 47 Japan Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 48 Japan Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 49 Japan Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 50 Japan Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 51 China Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 52 China Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 53 China Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 54 China Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 55 India Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 56 India Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 57 India Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 58 India Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD)



Million)

Table 59 South Korea Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 60 South Korea Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 61 South Korea Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 62 South Korea Spinal Muscular Atrophy Treatment Market, By Drug, 2018 -2030 (USD Million)

Table 63 Australia Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 64 Australia Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 65 Australia Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 66 Australia Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 67 Latin America Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 68 Latin America Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 69 Latin America Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 70 Latin America Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 71 Brazil Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 72 Brazil Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 73 Brazil Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 74 Brazil Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 75 Mexico Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 76 Mexico Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 77 Mexico Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)



Table 78 Mexico Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 79 Argentina Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 80 Argentina Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 81 Argentina Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 82 Argentina Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 83 Middle East & Africa Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 84 Middle East & Africa Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 85 Middle East & Africa Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 86 Middle East & Africa Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 87 Saudi Arabia Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 88 Saudi Arabia Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 89 Saudi Arabia Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 90 Saudi Arabia Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 91 South Africa Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 92 South Africa Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 93 South Africa Spinal Muscular Atrophy Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)

Table 94 South Africa Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)

Table 95 UAE Spinal Muscular Atrophy Treatment Market, By Type, 2018 - 2030 (USD Million)

Table 96 UAE Spinal Muscular Atrophy Treatment Market, By Treatment, 2018 - 2030 (USD Million)

Table 97 UAE Spinal Muscular Atrophy Treatment Market, By Route of Administration,



2018 - 2030 (USD Million)

Table 98 UAE Spinal Muscular Atrophy Treatment Market, By Drug, 2018 - 2030 (USD Million)



List Of Figures

LIST OF FIGURES

- Fig. 1 Spinal Muscular Atrophy Treatment market segmentation
- Fig. 2 Market research process
- Fig. 3 Data triangulation techniques
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 QFD modeling for market share assessment
- Fig. 8 Market formulation & validation
- Fig. 9 Spinal Muscular Atrophy Treatment market snapshot
- Fig. 10 Parent market outlook
- Fig. 11 Related/ancillary market outlook, revenue, 2021, (USD Million)
- Fig. 12 Penetration and growth prospect mapping
- Fig. 13 Spinal muscular atrophy treatment market driver impact
- Fig. 14 Spinal muscular atrophy treatment market restraint impact
- Fig. 15 SWOT analysis, by factor (political & legal, economic, and technological)
- Fig. 16 Industry Analysis Porter's
- Fig. 17 Strategy mapping
- Fig. 18 Spinal muscular atrophy treatment market: Type outlook and key takeaways

Fig. 19 Spinal muscular atrophy treatment market: Type movement analysis & market share 2021 & 2030

Fig. 20 Type 1 market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 21 Type 2 market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 22 Type 3 market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 23 Type 4 market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 24 Spinal muscular atrophy treatment market: Treatment outlook and key takeaways

Fig. 25 Spinal muscular atrophy treatment market: Treatment movement analysis & market share 2021 & 2030

Fig. 26 Gene therapy market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 27 Drug market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 28 Spinal muscular atrophy treatment market: Drug outlook and key takeaways

Fig. 29 Spinal muscular atrophy treatment market: Drug movement analysis & market share 2021 & 2030

Fig. 30 Spinraza market estimates and forecast, 2018 - 2030 (USD Million)

Fig. 31 Zolgensama market estimates and forecast, 2018 - 2030 (USD Million)



Fig. 32 Evrysdi market estimates and forecast, 2018 - 2030 (USD Million)

- Fig. 33 Other market estimates and forecast, 2018 2030 (USD Million)
- Fig. 34 Spinal muscular atrophy treatment market : Regional outlook and key takeaways
- Fig. 35 Regional outlook, 2021 & 2030
- Fig. 36 North America
- Fig. 37 North America market estimates and forecast, 2018 2030 (USD Million)
- Fig. 38 U.S.
- Fig. 39 U.S. market estimates and forecast, 2018 2030 (USD Million)
- Fig. 40 Canada
- Fig. 41 Canada market estimates and forecast, 2018 2030 (USD Million)
- Fig. 42 Europe
- Fig. 43 Europe market estimates and forecast, 2018 2030 (USD Million)
- Fig. 44 U.K.
- Fig. 45 U.K. market estimates and forecast, 2018 2030 (USD Million)
- Fig. 46 Germany
- Fig. 47 Germany market estimates and forecast, 2018 2030 (USD Million)
- Fig. 48 France
- Fig. 49 France market estimates and forecast, 2018 2030 (USD Million)
- Fig. 50 Italy
- Fig. 51 Italy market estimates and forecast, 2018 2030 (USD Million)
- Fig. 52 Spain
- Fig. 53 Spain market estimates and forecast, 2018 2030 (USD Million)
- Fig. 54 Asia Pacific
- Fig. 55 Asia Pacific market estimates and forecast, 2018 2030 (USD Million)
- Fig. 56 Japan
- Fig. 57 Japan market estimates and forecast, 2018 2030(USD Million)
- Fig. 58 China
- Fig. 59 China market estimates and forecast, 2018 2030 (USD Million)
- Fig. 60 India
- Fig. 61 India market estimates and forecast, 2018 2030 (USD Million)
- Fig. 62 South Korea
- Fig. 63 South Korea market estimates and forecast, 2018 2030 (USD Million)
- Fig. 64 Australia
- Fig. 65 Australia market estimates and forecast, 2018 2030 (USD Million)
- Fig. 66 Latin America
- Fig. 67 Latin America market estimates and forecast, 2018 2030 (USD Million)
- Fig. 68 Brazil
- Fig. 69 Brazil market estimates and forecast, 2018 2030 (USD Million)
- Fig. 70 Mexico



- Fig. 71 Mexico market estimates and forecast, 2018 2030 (USD Million)
- Fig. 72 Argentina
- Fig. 73 Argentina market estimates and forecast, 2018 2030 (USD Million)
- Fig. 74 Middle East & Africa
- Fig. 75 MEA market estimates and forecast, 2018 2030 (USD Million)
- Fig. 76 South Africa
- Fig. 77 South Africa market estimates and forecast, 2018 2030 (USD Million)
- Fig. 78 Saudi Arabia
- Fig. 79 Saudi Arabia market estimates and forecast, 2018 2030 (USD Million)
- Fig. 80 UAE
- Fig. 81 UAE market estimates and forecast, 2018 2030 (USD Million)
- Fig. 82 Market differentiators
- Fig. 83 Key company market share analysis, 2021
- Fig. 84 Company market position analysis
- Fig. 85 Competitive dashboard analysis
- Fig. 86 Regional network map



I would like to order

- Product name: Spinal Muscular Atrophy Treatment Market Size, Share & Trends Analysis Report By Type (Type1, Type 2), By Treatment (Gene Therapy, Drug), By Drug (Spinraza, Zolgensma), By Route Of Administration, By Region, And Segment Forecasts, 2022 -2030
 - Product link: https://marketpublishers.com/r/S30148EDCBEEN.html
 - Price: US\$ 5,950.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/S30148EDCBEEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature ____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>



To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970